Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potent dipeptide inhibitors of the pp60c-src SH2 domain.
Pacofsky GJ, Lackey K, Alligood KJ, Berman J, Charifson PS, Crosby RM, Dorsey GF Jr, Feldman PL, Gilmer TM, Hummel CW, Jordan SR, Mohr C, Shewchuk LM, Sternbach DD, Rodriguez M. Pacofsky GJ, et al. Among authors: alligood kj. J Med Chem. 1998 May 21;41(11):1894-908. doi: 10.1021/jm970853a. J Med Chem. 1998. PMID: 9599239
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM, Lackey K. Rusnak DW, et al. Among authors: alligood kj. Cancer Res. 2001 Oct 1;61(19):7196-203. Cancer Res. 2001. PMID: 11585755
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.
Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM, Shewchuk L. Wood ER, et al. Among authors: alligood kj. Cancer Res. 2004 Sep 15;64(18):6652-9. doi: 10.1158/0008-5472.CAN-04-1168. Cancer Res. 2004. PMID: 15374980
Peptide inhibitors of src SH3-SH2-phosphoprotein interactions.
Gilmer T, Rodriguez M, Jordan S, Crosby R, Alligood K, Green M, Kimery M, Wagner C, Kinder D, Charifson P, et al. Gilmer T, et al. J Biol Chem. 1994 Dec 16;269(50):31711-9. J Biol Chem. 1994. PMID: 7527393 Free article.
The formation of a covalent complex between a dipeptide ligand and the src SH2 domain.
Alligood KJ, Charifson PS, Crosby R, Consler TG, Feldman PL, Gampe RT Jr, Gilmer TM, Jordan SR, Milstead MW, Mohr C, Peel MR, Rocque W, Rodriguez M, Rusnak DW, Shewchuk LM, Sternbach DD. Alligood KJ, et al. Bioorg Med Chem Lett. 1998 May 19;8(10):1189-94. doi: 10.1016/s0960-894x(98)00195-4. Bioorg Med Chem Lett. 1998. PMID: 9871733
Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.
Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, Degenhardt Y, Rudolph SK, Haws TF Jr, Hudson-Curtis BL, Gilmer TM. Rusnak DW, et al. Among authors: alligood kj. Cell Prolif. 2007 Aug;40(4):580-94. doi: 10.1111/j.1365-2184.2007.00455.x. Cell Prolif. 2007. PMID: 17635524 Free PMC article.
14 results